EGFR and non-small cell lung carcinoma: EGFR mutation is a potent indicator of EGFR-TKIs efficiency in advanced NSCLC therapy, yet about 20–30% of EGFR-mutated cases exhibited no response to EGFR-TKIs, suggesting the presence of other factors independent of EGFR mutation [80,151,152,153].